[go: up one dir, main page]

MX2019010530A - Alfavirus recombinantes atenuados incapaces de replicarse en mosquitos y usos de estos. - Google Patents

Alfavirus recombinantes atenuados incapaces de replicarse en mosquitos y usos de estos.

Info

Publication number
MX2019010530A
MX2019010530A MX2019010530A MX2019010530A MX2019010530A MX 2019010530 A MX2019010530 A MX 2019010530A MX 2019010530 A MX2019010530 A MX 2019010530A MX 2019010530 A MX2019010530 A MX 2019010530A MX 2019010530 A MX2019010530 A MX 2019010530A
Authority
MX
Mexico
Prior art keywords
replicating
mosquitoes
attenuated recombinant
incapable
equine encephalitis
Prior art date
Application number
MX2019010530A
Other languages
English (en)
Other versions
MX378503B (es
Inventor
c weaver Scott
Frolova Elena
V Frolov Ilya
Original Assignee
Univ Texas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Texas filed Critical Univ Texas
Publication of MX2019010530A publication Critical patent/MX2019010530A/es
Publication of MX378503B publication Critical patent/MX378503B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C12N7/04—Inactivation or attenuation; Producing viral sub-units
    • C12N7/045—Pseudoviral particles; Non infectious pseudovirions, e.g. genetically engineered
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36161—Methods of inactivation or attenuation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36171—Demonstrated in vivo effect
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La presente invención describe un alfavirus recombinante atenuado que es incapaz de replicarse en las células de mosquito y de transmitirse mediante los vectores de mosquitos. Este alfavirus atenuado podría incluir pero no se limita al virus de la Encefalitis Equina Occidental, virus de encefalitis Equina Oriental, virus de Encefalitis Equina Venezolana o virus de Chikungunya. La presente invención también describe el método de generación de tales alfavirus y su uso como composiciones inmunogénicas.
MX2019010530A 2008-01-24 2009-01-23 Alfavirus recombinantes atenuados incapaces de replicarse en mosquitos y usos de estos. MX378503B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US6222908P 2008-01-24 2008-01-24
PCT/US2009/000458 WO2009131604A2 (en) 2008-01-24 2009-01-23 Attenuated recombinant alphaviruses incapable of replicating in mosquitoes and uses thereof

Publications (2)

Publication Number Publication Date
MX2019010530A true MX2019010530A (es) 2019-10-15
MX378503B MX378503B (es) 2025-03-11

Family

ID=41217313

Family Applications (3)

Application Number Title Priority Date Filing Date
MX2019010530A MX378503B (es) 2008-01-24 2009-01-23 Alfavirus recombinantes atenuados incapaces de replicarse en mosquitos y usos de estos.
MX2014010258A MX367792B (es) 2008-01-24 2009-01-23 Alfavirus recombinantes atenuados incapaces de replicarse en mosquitos y usos de estos.
MX2010007989A MX2010007989A (es) 2008-01-24 2009-01-23 Alfavirus recombinantes atenuados incapaces de replicarse en mosquitos y usos de estos.

Family Applications After (2)

Application Number Title Priority Date Filing Date
MX2014010258A MX367792B (es) 2008-01-24 2009-01-23 Alfavirus recombinantes atenuados incapaces de replicarse en mosquitos y usos de estos.
MX2010007989A MX2010007989A (es) 2008-01-24 2009-01-23 Alfavirus recombinantes atenuados incapaces de replicarse en mosquitos y usos de estos.

Country Status (15)

Country Link
US (3) US8426188B2 (es)
EP (2) EP2250269B1 (es)
JP (1) JP5758632B2 (es)
KR (2) KR101913790B1 (es)
CN (1) CN102083986B (es)
AU (1) AU2009238667A1 (es)
CA (2) CA2910235C (es)
CO (1) CO6290702A2 (es)
IL (2) IL207167A (es)
MX (3) MX378503B (es)
MY (1) MY178870A (es)
NZ (2) NZ587502A (es)
SG (2) SG187513A1 (es)
WO (1) WO2009131604A2 (es)
ZA (1) ZA201005943B (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2183368B1 (en) * 2007-06-21 2016-08-10 Alphavax, Inc. Promoterless cassettes for expression of alphavirus structural proteins
NZ587502A (en) 2008-01-24 2012-12-21 Univ Texas Attenuated recombinant alphaviruses incapable of replicating in mosquitoes and uses thereof
US8961995B2 (en) 2012-09-20 2015-02-24 Uab Research Foundation Methods and compositions for alphavirus replicons
EP2900685B1 (en) 2012-09-27 2017-10-25 Research Development Foundation Attenuated chikungunya virus
MX361342B (es) 2013-03-14 2018-12-04 Takeda Vaccines Inc Composiciones y metodos para formulaciones de alfavirus vivos atenuados.
CN109195625A (zh) * 2016-03-31 2019-01-11 武田疫苗股份有限公司 活减毒甲病毒构建体及其方法和用途
PH12018502460B1 (en) * 2016-05-27 2023-11-08 Univ Griffith Arthrogenic alphavirus vaccine
KR20200003390A (ko) 2017-05-08 2020-01-09 그릿스톤 온콜로지, 인코포레이티드 알파바이러스 신생항원 벡터
WO2020028749A1 (en) * 2018-08-03 2020-02-06 Uab Research Foundation Methods and compositions for alphavirus vaccine
CN109536464B (zh) * 2018-12-10 2022-06-10 中国科学院武汉病毒研究所 一种缺失衣壳蛋白基因的基孔肯雅病毒感染性克隆及构建方法和在制备减毒疫苗中的应用
WO2020243719A1 (en) 2019-05-30 2020-12-03 Gritstone Oncology, Inc. Modified adenoviruses
IL294290A (en) 2019-12-31 2022-08-01 Elixirgen Therapeutics Inc Temperature-based transient delivery of nucleic acids and proteins to cells and tissues
CN116438308A (zh) 2020-08-06 2023-07-14 磨石生物公司 多表位疫苗盒

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6451592B1 (en) * 1996-04-05 2002-09-17 Chiron Corporation Recombinant alphavirus-based vectors with reduced inhibition of cellular macromolecular synthesis
CA2327189A1 (en) * 2000-12-21 2002-06-21 The Minister Of National Defence Novel dna-based vaccine against the encephalitis alphaviruses
KR101518309B1 (ko) * 2003-03-20 2015-05-08 알파벡스, 인크. 개선된 알파바이러스 레플리콘 및 헬퍼 구축물
AU2005256112B9 (en) 2004-07-30 2008-09-25 Blackberry Limited Method and system for coordinating device setting between a communications client and its host device
US7332322B2 (en) * 2004-09-14 2008-02-19 Ilya Frolov Venezuelan equine encephalitis virus replicons with adaptive mutations in the genome and uses thereof
CA2579507C (en) 2006-03-15 2017-06-13 Institut Pasteur Novel isolated and purified strains of chikungunya virus and polynucleotides and polypeptides sequences, diagnostic and immunogenical uses thereof
NZ587502A (en) 2008-01-24 2012-12-21 Univ Texas Attenuated recombinant alphaviruses incapable of replicating in mosquitoes and uses thereof

Also Published As

Publication number Publication date
EP2250269A4 (en) 2012-01-04
IL232032A0 (en) 2014-05-28
CN102083986B (zh) 2014-06-18
JP2011523347A (ja) 2011-08-11
US20110052634A1 (en) 2011-03-03
KR101913790B1 (ko) 2018-12-28
US9580690B2 (en) 2017-02-28
US8426188B2 (en) 2013-04-23
ZA201005943B (en) 2011-04-28
CN102083986A (zh) 2011-06-01
EP2250269B1 (en) 2016-03-16
NZ603790A (en) 2014-08-29
CA2910235C (en) 2021-07-06
KR101668849B1 (ko) 2016-10-24
NZ587502A (en) 2012-12-21
EP3085787A1 (en) 2016-10-26
EP3085787B1 (en) 2020-10-28
KR20160124255A (ko) 2016-10-26
IL207167A (en) 2014-04-30
MX2010007989A (es) 2010-12-21
CA2713165C (en) 2015-12-29
WO2009131604A3 (en) 2009-12-23
MX378503B (es) 2025-03-11
CA2910235A1 (en) 2009-10-29
CO6290702A2 (es) 2011-06-20
US10533186B2 (en) 2020-01-14
CA2713165A1 (en) 2009-10-29
JP5758632B2 (ja) 2015-08-05
WO2009131604A2 (en) 2009-10-29
IL207167A0 (en) 2010-12-30
US20170240919A1 (en) 2017-08-24
SG10201606111XA (en) 2016-09-29
US20140010841A1 (en) 2014-01-09
AU2009238667A1 (en) 2009-10-29
MX367792B (es) 2019-09-05
KR20100106599A (ko) 2010-10-01
SG187513A1 (en) 2013-02-28
MY178870A (en) 2020-10-21
EP2250269A2 (en) 2010-11-17

Similar Documents

Publication Publication Date Title
MX2019010530A (es) Alfavirus recombinantes atenuados incapaces de replicarse en mosquitos y usos de estos.
ECSP23013715A (es) Composiciones y métodos de construcciones quiméricas del virus del dengue en vacunas
MX2020001490A (es) Metodos para producir composiciones de celulas geneticamente modificadas y composiciones relacionadas.
ECSP18081582A (es) Constructos de alfavirus vivo atenuado y métodos y usos de los mismos
CO6761348A2 (es) Compuestos antivirales
UY37564A (es) Aislados de lysinibacillus y usos de los mismos
MX375431B (es) Virus de la enfermedad de newcastle y usos de los mismos.
BR112017001049A2 (pt) material biocomposto anisotrópico, implantes médicos contendo o mesmo e métodos de tratamento do mesmo
ECSP12011939A (es) Compuestos Lipopéptidos y métodos relacionados
CL2012002157A1 (es) Metodo de estabilizacion fisica que comprende combinar particulas gruesas con suspension de particulas finas para generar suspension compuesta y mezclar con polimero superabsorbente para producir suspension composicion semi-solida transportable.
UY36157A (es) Composiciones pesticidas y procedimientos relacionados con las mismas
MX385549B (es) Composición tipo azeótropo de hexafluoropropano, hexafluoropropeno y fluoruro de hidrógeno.
MX387756B (es) Composiciones de matríces extracelulares.
CO2017000030A2 (es) Moléculas que tienen cierta utilidad plaguicida e intermediarios, composiciones y procedimientos relacionados con las mismas
CO2017004735A2 (es) Moléculas que tienen utilidad plaguicida e intermediarios, composiciones y procedimientos relacionados con las mismas
WO2015095735A3 (en) Vaccine compositions and uses thereof
CL2012003710A1 (es) Material celulosico que tiene uno o mas diluyentes del humo dentro de su estructura celular en que el peso de dicho diluyente del humo es mayor o igual al 5 % en base al peso seco del material celulosico; metodo de preparacion de dicho material, y su uso.
BR112015013071A2 (pt) solução de trombina e seus métodos de uso
NZ631012A (en) Compositions and methods for live, attenuated alphavirus formulations
MX370211B (es) Eteres de bis (hidroximetil) ciclohexanos.
BR112016002086A2 (pt) materiais de lignina contendo composições
PE20190149A1 (es) Composiciones y metodos para estabilizar alfavirus con formulaciones mejoradas
EP2504029A4 (en) COMPOSITIONS, METHODS AND USES FOR THE EXPRESSION OF PEPTIDES ASSOCIATED WITH ENTEROBACTERIA
TR201109452U (tr) Bitlenmeyi engelleyen sabun.
UY31649A1 (es) Cierto nitrógeno que contiene entidades químicas bicíclicas para tratar infecciones virales.